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use determined that early revisions/reoperations were more frequent in HR than 
in THA (range 3.1-13.1 vs. 1.9-7.5 per 1000 person years, respectively). 
CONCLUSIONS: This systematic review provides clinicians and health policy 
makers with information on adverse events based on device type and market 
status. Rates of adverse events vary by device type, making it challenging to 
conclude which device is more effective. Findings highlight the importance of 
differentiating market status and standardizing exposure time by 1000 person 
years to facilitate comparisons between studies.  
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OBJECTIVES: Colchicine was originally used, and continues to be used, to treat 
rheumatic diseases. It is used most frequently for the treatment of gout but is 
also used to treat familial Mediterranean fever, pericarditis, and Behcet’s disease. 
However, because of its pharmacokinetics, colchicine can interact dangerously 
with other drugs. The objective of the study was to analyze the association 
between drug-drug interactions involving colchicine and major adverse events 
as reported in the U.S. FDA Adverse Event Reporting System (FAERS). METHODS: 
All major adverse events (including death, initial or prolonged hospitalization, 
and persistent or significant disability) related to colchicine between 2004 and 
2011 were retrieved from FAERS. Then, events evidently caused by interactions 
with drugs (such as atazanavir, clarithromycin, indinavir, itraconazole, 
ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, 
cyclosporine, and ranolazine) were distinguished from events evidently caused 
by colchicine as the primary suspect drug. Major adverse event rates were 
calculated. RESULTS: Between 2004 and 2011, a total of 2655 adverse event 
reports involving colchicine interactions with other drugs were found in the 
FAERS database, of which 718 reported a death (implying a fatality ratio of 
27.0%), 762 reported a hospitalization (giving a 28.7% hospitalization rate), 78 
referred to life-threatening events, and 56 reported disability. Pancytopenia, 
renal failure, vomiting, drug toxicity, and diarrhea were the most common 
reported events. There were 4,717 reports involving colchicine as the primary 
suspect drug, of which 527 reported a death (fatality ratio of 11.2%). A 
statistically significant (p<0.001) difference between the two fatality ratios was 
found. CONCLUSIONS: When combined with certain other drugs, evidence 
suggests that colchicine may be associated with a relatively high death rate, 
especially if not dosed appropriately. In light of the current data, physicians 
should be keenly aware of all potentially fatal drug-drug interactions and follow 
therapeutic guidelines on using colchicine.  
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OBJECTIVES: Despite risk of mortality, traffic-related injuries place a significant 
financial burden on the health sector, especially due to costs like intensive  
care unit (ICU) admission and prolonged hospital stays. The aim of the study is 
to investigate risk factors of admission to the ICU among injured-patients 
admitted to a large urban trauma center in Saudi Arabia. METHODS: This 
analysis was performed using a dataset from King Abdulaziz Medical City  
in Riyadh, Saudi Arabia. 7,859 patients met the inclusion criteria during the 
study period (injured due to falls or traffic crashes and admitted to the hospital 
between years 2001-2010). Backward-stepwise logistic regression, with admission 
to the ICU as the outcome, was performed. Variables with p-values<0.1  
were included in the final model. Model discrimination was evaluated using the 
Area Under the Curve (AUC). RESULTS: A total of 1833 injured individuals (23.3%) 
were admitted into the ICU during the study period. They had longer hospital 
stay and were more likely to be males, sustain head injuries, and to undergo 
surgery. Multivariate analysis identified injury severity score, Glasgow coma 
scale, injury mechanism, head injury, and direct transfer to surgery as 
significant predictors of admission to the ICU. The results indicate that 
compared to falls, all traffic-related injuries were significantly more likely lead to 
ICU admission (occupants OR=2.5, [95% CI: 2.0-3.0]; pedestrians OR=2.7, [95% CI: 
2.1-3.4]; motorcycle OR=1.7, [95% CI: 1.1-2.7]) adjusting for other covariates. The 
model showed excellent discrimination ability as shown by [AUC=0.90]. 
CONCLUSIONS: This model can facilitates the triage process of injured patients 
by assisting in identify those at higher risk of ICU admission. Unlike the U.S, 
emergency health care services are free in Saudi Arabia and costs are mostly 
absorbed by the admitting hospital. Therefore, public health interventions are 
needed to alleviate the burden traffic injuries place on health care settings and 
improve population health.  
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OBJECTIVES: Long-term use of oral glucocorticoid (OGC) therapy may be 
associated with adverse effects; thus, OGC-sparing approaches to treatment of 
rheumatoid arthritis (RA) may benefit patients. This study examined OGC use in 
rituximab-treated RA patients with prior exposure to anti-tumor necrosis factor-
alpha (anti-TNF) therapy. METHODS: Administrative claims-based retrospective 
study. Study patients met the following criteria: initiated rituximab between 
March 1, 2006-March 31, 2011 (initiation date=index) after exposure to anti-TNF 
therapy, aged ≥18 years, had a medical claim with a diagnosis code for RA (ICD-9-
CM 714.0x) between January 1, 2004-March 31, 2011, continuously enrolled for 12 
months before and ≥90 days after index, had no medical claims with diagnosis 
codes for non-RA indications of biologic disease modifying antirheumatic drugs 
(BDMARDs) within 12 months before index. Using rituximab infusion dates and 
the recommended administration frequency schedule, rituximab exposure 
periods were constructed. Exposure periods commenced upon index and 
terminated at the first occurrence of switch to a different BDMARD, 90-day gap in 
rituximab treatment, loss to follow-up, or follow-up of 36 months. Outcomes 
were any OGC use and mean daily OGC dose expressed in prednisone equivalent 
and averaged among all patients, measured throughout the exposure period in 
sequential 90-day intervals. Multivariable generalized estimating equation 
models tested for statistically significant changes in OGC use over time. 
RESULTS: Study included 1,763 rituximab exposure periods (1,718 unique 
patients); mean age 54.9 years, 81.5% female, 54.0% with OGC use within 30 days 
before index. Between the first and last 90-day intervals, the probability of OGC 
use and the mean daily OGC dose decreased significantly: from 0.56 to 0.36 
(p<0.001) and from 3.5mg/day to 2.7mg/day (primarily driven by OGC 
discontinuation) (p<0.001), respectively. Sensitivity analyses subset to exposure 
periods lasting a full 36 months yielded similar results. CONCLUSIONS: 
Statistically significant decreases in OGC use were observed in rituximab-treated 
RA patients with prior exposure to anti-TNF therapy.  
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OBJECTIVES: To identify features that characterize difficult-to-treat gout patients 
based on the number of flares experienced within a 12-month period. METHODS: 
A retrospective database analysis was conducted using electronic medical 
records, laboratory reports and demographic data files. Eligible patients were 
above 18 years, with at least one diagnosis of gout and/or a gout-related 
medication between January 1, 2005 and December 31, 2010. Patients with at 
least one serum uric acid value and at least one flare were followed for 12 
months from the date the first flare was reported. Eligible patients who had no 
flares within the study period were also included. RESULTS: A total of 266 
patients met study criteria, the mean age (±SD) was 61.2 years (±15.7), the 
majority were males (n=180; 67.7%), the mean annual flare rate was 1.80 (±1.11), 
and the mean serum uric acid value was 7.24mg/dl (±2.07). Based on three 
categories of flare rates, 110 patients (41.4%) had no flares, 107 patients (40.2%) 
had one or two flares, and 49 patients (18.4%) had at least 3 flares. ANOVA tests 
detected significant differences in mean serum uric acid values by flare rate 
(F=18.34; df=2; p<0.0001). Kruskal-Wallis results indicated a significant 
relationship between serum uric acid l ˂evel categories (  6.0 mg/dl, ≥6.0-  ˂9.0 mg/dl 
and ≥9.0 mg/dl) and flare rates; X2=32.26; df=2; p<0.0001. There was no significant 
difference in flare rate by age (F=0.31; df=2; p=0.7355). Although Wilcoxon results 
showed a significant relationship between serum uric acid level categories and 
gender (X2=7.10; df=1; p=0.0077), no significant relationship between flare rates 
and gender (X2=1.67; df=1; p=0.1959) was observed. CONCLUSIONS: More 
information is required to be able to identify and characterize difficult-to-treat 
gout patients.  
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OBJECTIVES: To compare the disease status and outcomes of patients with AS 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of AS patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5AS biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1095 eligible AS patient charts were 
abstracted; 935 (85%) patients were on their first biologic (mean-age:42.6yrs, 
female:20%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France/Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis (range:28month 
(Italy)-59month (France)) and time-on-current biologic (range:24month 
(UK/Germany/Italy)-27month (France)) differed within 5EU. Among the top-3 
reasons for biologic treatment initiation, ‘mechanism of action’ & ‘improve 
signs/symptoms’ were observed across 5EU, whereas ‘positive personal 
experience’ (UK/Germany/France) and ‘preservation of structural damage’ 
(Italy/Spain) were also observed. Key lab measures documented were: ESR 
